GovWire

Ten leading experts have joined the Advisory Council on the Misuse of Drugs (ACMD) to strengthen its vital work advising the government on drug harms.

A document developed by the Advisory Council on the Misuse of Drugs (ACMD) to outline the governing process for preparing evidence-based advice.

Overview of the Advisory Council on the Misuse of Drugs' (ACMD) work from January 2020 to December 2022.

Occupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD).

A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.

The Advisory Council on the Misuse of Drugs responds to the government on their proposal to amend the licensing regimen for industrial hemp.

Occupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD).

The Advisory Council on the Misuse of Drugs has provided an updated harms assessment of alkyl nitrites.

The Novel Psychoactive Substances Committee (NPSC) is seeking evidence for its review of the evidence of the misuse and harms of synthetic cathinones in the UK.

A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.

The Advisory Council on the Misuse of Drugs has provided an updated harms assessment of alkyl nitrites.

ACMD work programme 2024 letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD).

A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.

A review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update).

A review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update).

This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.

This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.

Government response to the third addendum to the Advisory Council on the Misuse of Drugs' report on 2-benzyl benzimidazole and piperidine benzimidazolone opioids.

Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.

Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.

Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.

ACMD work programme 2024 letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD).

Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.

The Advisory Council on the Misuse of Drugs (ACMD) seeks to gather insight into current government-led drug prevention policies and landscape across the UK.

Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.

The Advisory Council on the Misuse of Drugs call for evidence, collecting written evidence to better understand internet-facilitated drug markets (IFDMs).

A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.

Fifteen new synthetic opioids and 5 other drugs will be banned as Class A drugs as the government continues to act to prevent drug deaths.